Bone marrow (BM) stromal cell inhibition of leukemic cell dWrentiation was studied in cellular coculture experiments. In coculture, a significant percentage of cells from the human myeloid leukemic c e l l lines HL-80, PLB-985, and K562 adhere to fibroblastic KM-l02 BM stromal cells. A sensitive twocolor immunotluoroscence assay was developed to monitor stromal cellular effects upon leukemic cell differentiation. After chemical induction with lrr25-dihydroxyvitamin Dg, strongly adherent HL-60 and PLB-985 cells were inhibeed from differmtiating into more mature monocytic cells, as measured by the monocytic surface marker CD14. In contrast, loosely adherent and nonadherent HL-60 and PLB-985 leukemic cells in the same cocultures, as well as both adher-T HE BONE MARROW (BM) serves as an important reservoir for leukemic cells in the clinical setting.'Pz3 Whereas relatively little is known about the cellular determinants within the BM compartment that promote leukemic cell escape during therapy, it has been presumed that BM stromal cells may be one such critical determinant? Because a growing body of data now support the notion that direct cell-cell interactions play an essential role in BM stromal cell regulation of normal h e m a t o p~i e s i s~~~' it is tempting to speculate that such interactions also mediate stromal cell regulation of leukemic cells.
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reservoir for leukemic cells in the clinical setting.'Pz3 Whereas relatively little is known about the cellular determinants within the BM compartment that promote leukemic cell escape during therapy, it has been presumed that BM stromal cells may be one such critical determinant? Because a growing body of data now support the notion that direct cell-cell interactions play an essential role in BM stromal cell regulation of normal h e m a t o p~i e s i s~~~' it is tempting to speculate that such interactions also mediate stromal cell regulation of leukemic cells.
BM stromal cells are essential for the initiation and longterm maintenance of normal hematopoiesis in vitro: It is known that primitive hematopoietic progenitors reside in the adherent stromal cell layer of long-term BM culturesg presumably providing a setting for hematopoietic stem cells to maintain their self-renewal capacity? There is evidence that direct intercellular adherence may similarly be important for stromal cell-mediated inhibition of the differentiation capacity of leukemic cells. This data is largely based upon simplified systems involving stromal and leukemic cell coculture. Most significantly, Ohkawa and Harigaya" showed that the small percentage of HL-60 myeloid leukemic cells that adhere to KM-l02 human BM stromal cells are blocked in both proliferative capacity and responsiveness to a differentiation inducer. In contrast, nonadherent HL-60 cells in coculture differentiated unperturbed. Significantly, differentiation and proliferation blockade were reversible. Though low in numbers, such adherent cells could be clinically significant by representing a potential reservoir of leukemic cells refractory to antiproliferative and/or differentiation-inducing drugs.
The study of Harigaya and coworkers was restricted to a single leukemic cell line, namely HL-60. In the present study, we have expanded the analyses to encompass leukemic lines other than HL-60, and in parallel, we have developed alternative experimental strategies that are better suited for such differentiation analyses in diverse leukemic cell backgrounds. Several new insights have emerged from these studies. Most significantly, we now document significant differences among leukemic lines with respect to their susceptibility to differentiation blockade. Moreover, our findings provide insights into the mechanism that may account for these differences. Our data suggest that there are qualitative differences in the way distinct leukemic cells bind to stromal cells, and hence, that intercellular adherence is not a simple all-or-none phenomenon.
MATERIALS AND METHODS
Cell culture. The KM-102 stromal cells (kindly provided by Dr Harigaya) were maintained in McCoy's 5a medium (GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (BioWhittaker, Walkerville, MD)/10 mmol/L HEPESIIIO pg per mL gentamicin sulfate (GIBCO) in a humid 5% CO, atmosphere at 37°C. The cells were passaged with trypsin/EDTA upon their reaching near confluence. The leukemic cell lines were maintained under the same conditions except for using RPM1 1640 medium (GIBCO). For cocultures, KM-l02 cells were grown to 50% confluence before adding the leukemic or human BM cells (kindly provided by Dr S. Gerson, Ireland Cancer Center, Case Western Reserve University; obtained with consent). After a 2-day (or 6-day for BM cultures) incubation period, cultures were gently agitated, then washed twice with complete medium to remove nonadherent cells, before observation. It should be noted that although primary BM cells showed significant adherence after 2 days, adhesion increased up to 6 days. B -I O 2 blockade of leukemic cell differentiation. 
RESULTS
In baseline experiments, adherence between KM-l02 human BM stromal cells and several human myeloid leukemic lines was assessed histologically. Each of the leukemic lines was cocultured with plastic-adherent KM-l02 cells for 2 days, and subsequently, leukemic cells not bound to stromal cells were removed by gentle agitation. The photomicrographs shown in Fig 1 illustrate the different degrees of adhesion observed for the various leukemic lines. K562" cells ( Fig 1A) exhibited extensive adhesion to the stromal underlayer, decorating most of the stromal cell surfaces. All of the remaining leukemic lines adhered to a lesser extent, with a hierarchy of adherence ranging from maximal adherence by HL-60" cells (Fig lB) , slightly less adherence by PLB-985I3 cells (Fig IC) , and little adherence by U937" cells ( Fig 1D) . In view of the relatively short coculture period (2 days), as well as the loss of proliferation capacity previously documented for stromal cell-bound HL-60 cells," the adhesion differences seen in these photomicrographs are not likely to be a consequence of differences in leukemic cell proliferative potential.
For comparison purposes, we assessed the capacity of CD34' hematopoietic progenitors derived from normal human BM to bind to KM-l02 cells. Adherent CD34+ cells were detected by immunostaining with fluorescein-conjugated anti-CD34 antibodies. After 6 days of coculture, extensive adherence of CD34' cells to stromal cells was noted (Fig 1 , E and F) .
In view of the limitations of the nitroblue tetrazolium (NBT) assay previously used for monitoring leukemic differentiation and documenting stromal-mediated differentiation blockade (see Discussion), we developed an alternative method for monitoring stromal-blockade of leukemic differentiation. This method was based upon two-coior immunofluorescence, and in the case of HL-60 and PLB-985 cells, used a combination of anti-CD18 and anti-CD14 antibodies in double immunostaining. The anti-CD18 antibody (reactive with the common , B chain of the LFA-l, Mac-1, and gp150,95 integrins) was used as a specific marker to identify all of the myeloid leukemic cells,I4 both uninduced and induced, that are present in the coculture, including those that blend into the stromal cell underlayer. Simultaneously, the anti-CD14 antibody was used on the same cells as a specific marker to identify those leukemic cells undergoing terminal monocytic differentiation.I5 Whereas the anti-CD18 antibody was visualized with a secondary rhodamine-conjugated goat antimouse IgG, the anti-CD14 antibody was directly fluorescein-conjugated. Neither antibody reacted with KM-102 cells (data not shown). It should be noted that the double immunofluorescence method inherently controls for antibody accessibility, that is, if CD18 is detectable, CD14 should be detectable as well.
We first applied the two-color immunofluorescence proce- most HL-60 (and PLB-985; data not shown) were, as expected,I6 both CD14+ and CD18+ (Fig 2A; Fig 3, A through  D) . Notably, in the double-exposure immunofluorescence photomicrograph (Fig 3D) , the double-positive CD18+(red)/ CD14+(green) cells appeared yellow.
We next determined whether there are soluble factors produced by stromal cells that may influence leukemic differentiation. Nonadherent leukemic cells were recovered after 2 days of coculture, placed inside of cell culture inserts possessing a permeable membrane, and returned to stromal cultures. After additional coculture for 3 days in the presence of mom Ia,25-dihydroxyvitamin D3, the HL-60 cells were shown to express CD14 to a similar extent as was seen for leukemic cells not cocultured with stromal cells (Fig 2) . Hence, there was no evidence for stromal cell-derived soluble factors mediating differentiation blockade.
In contrast to these observations with nonadherent HL-60 cells, adherent HL-60 cells in cocultures did show evidence of differentiation blockade. HL-60 cells were coincubated for 2 days with KM-102, and after gentle washing to remove nonadherent cells, the KM-102-adherent leukemic cellular mixture (on coverslips) was exposed to fresh medium containing moln la,25-dihydroxyvitamin Ds for 3 days and then immunostained. The bound leukemic cells, identified within the stromal cell layer by their CD18 positivity (Fig 3F) , did not express the CD14 differentiation marker (Fig 3G) . Accordingly, bound HL-60 cells were not yellow upon double-exposure (Fig 3H) . Hence, whereas la.25-dihydroxyvitamin D3-induced HL-60 cells cocultured with KM-102 cells in cell culture inserts were able to differentiate normally, those in direct cell-cell contact with KM-l02 cells were blocked in their capacity to differentiate.
Although stromal cell effects upon proliferation were not directly assessed in this study, the observation that cocultures devoid of nonadherent leukemic cells showed limited increases in cellularity over several days (data not suggested an inhibitory effect upon proliferation. This is consistent with the prior observations of Ohkawa and Harigaya."
To determine whether stromal cell blockade of HL-60 differentiation is common to other leukemic lines, coculture experiments were performed in a similar fashion with two other lines. PLB-985 cells, which share I"60's neutrophilic and monocytic bipotential differentiative capacity,', showed the same stromal cell-mediated differentiation blockade by double immunofluorescence upon la,25-dihydroxyvitamin D3 induction towards the monocytic lineage (Fig 3, I through L) . Surprisingly, K562 cells, which previously had been shown to bind at high levels to stromal cells, were not blocked in their differentiation along the megakaryocytic lineage (as measured by gpIIIa surface expression)" after phorbol ester (lo-' m o m TPA) induction (Fig 3, M and N) . Because of low adherence, U937 cells could not be adequately assessed for stromal cell-directed differentiation effects. Hence, whereas at least one leukemic line other than HL-60 is susceptible to the stromal cell blockade, it is clear that some lines are not so inhibited.
To determine whether the differentiation blockade is reversible for HL-60 cells, HL-60 cells bound to KM-l02 cells were released by light trypsinization and recovered free of stromal cells by adhering the latter to plastic. These released HL-60 cells resumed proliferation and reacquired their differentiative potential, as measured by CD14-positivity (data not shown). We further showed that some of the released HL-60 cells will readhere to fresh KM-l02 cells and again become resistant to la,25-dihydroxyvitamin D,-induced differentiation (data not shown).
In the course of these experiments, we noted some variability in the extent of the stromal cell-mediated HL-60 blockade. This turned out to correlate with how vigorously the cocultures were washed to release nonadherent cells. Under less-vigorous washing conditions, a greater number of HL-60 cells remained bound to the stromal cells. It became apparent that many of these more loosely associated cells were in fact not blocked in their differentiative capacity. This raised the possibility that the variability in blockade seen with different adherent leukemic cells might reflect qualitative differences in adherence. This was in fact supported by more careful microscopic analyses. We observed that HL-60 cells embedded within the stromal cell layer, as judged by their focusing within the plane of the KM-l02 cells, were inhibited from differentiating. In contrast, leukemic cells focusing outside of the focal plane of the stromal cells were not so blocked (Fig 3, 0 through U) . In Fig 3, panels 0 through U all correspond to the same field of bound HL-60 cells. The tightly interacting HL-60 cells in panels 0, Q, and S were in the same focal plane as the stromal cells and did not express CD14 after exposure to inducer (panel S), whereas the more loosely adherent HL-60 cells not embedded within the "102 cells (panels P, R, and T)
were induced to terminally differentiate (panel T). Panel U is a double-exposure showing both differentiated (yellow) and undifferentiated (reddish-orange) cells in the same field.
To assess the intimacy of leukemic cell-stromal cell interaction in a more straightforward fashion, scanning electron microscopy (SEM) of cocultures was performed (Fig 4) .
When cultured alone, nondividing, contact-inhibited K" 102 cells are largely flat, with smooth surfaces, relatively devoid of microvilli, and often possess multiple long processes interconnecting neighboring stromal cells (Fig 4A) . In the cocultures, adherent HL-60 (Fig 4B) and PLB-985 (Fig 4C) cells can be clearly identified by virtue of their round appearance and generally dense microvillous surface morphology. Notably, they show both superficial and intimate associations with the stromal cells via interconnecting processes, multiple contact points, and at times blending into the stromal underlayer.
In striking contrast to the HL-60 and PLB-985 cocultures, K562 cocultures showed relatively superficial interaction between leukemic and stromal cells (Fig 4D) . Significantly, this correlates with the previously cited absence of stromal cell inhibitory effects on K562 cells.
As another measure of the intimacy of cell-cell interaction, we studied cytoplasmic dye transfer between stromal and leukemic cells. A dye-transfer technique was used that had been previously used to show endothelial cell-lymphocyte intercellular communication." KM-l02 cells were loaded with a membrane-permeable fluorescent dye, BCECF-AM, which after internalization, undergoes rapid conversion by intracellular esterases into a membrane impermeant acid, BCECF, trapping it in the cytoplasm. In initial experiments, dye transfer between stromal cells was documented by combining loaded and unloaded stromal cells and observing the transfer of dye from the round, nonadherent stromal cells to the flat, adherent stromal cells, often from one cell to the next (Fig 5, A and B) .
Cytoplasmic dye transfer from stromal cells to cocultured leukemic cells was next examined. Subconfluent KM-l02 cells were loaded with fluorescent dye, leukemic cells were For added to the cultures, and after 4 hours, cocultures were observed by fluorescence microscopy. Dye transfer to HL-60 (Fig 5C) and PLB-985 (Fig SE) cells was apparent, but only for those leukemic cells that were clearly adherent to stromal cells. In contrast, although many K562 cells bound to the stromal cells, dye transfer occurred only rarely (Fig  5G) . Thus, the differences between HL-60 and PLB-985 cells on the one hand, and K562 cells on the other, extended to cell contact-dependent pathways of communication.
DISCUSSION
Ohkawa and Harigaya" introduced a defined experimental system based upon the use of well-characterized cell lines in coculture for studying stromal-leukemic cellular interactions. Their original report was limited to a single leukemic line, namely, HL-60. Hence, the general relevance of their finding that HL-60 differentiation is inhibited by stromal cells was left unanswered. In the present study, we have developed a new stromal-leukemic cell coculture system to study HL-60 cells and additional leukemic cell lines. Significantly, our data indicate that there is heterogeneity among leukemic lines with respect to their susceptibility to stromal cell-mediated blockade of differentiation. Moreover, our findings offer clues with regard to critical cellular determinants that may account for differential leukemic cell susceptibility to stromal cell inhibition.
Principle findings of the present study can be summarized as follows: (1) Stromal cells inhibit chemically-induced leukemic differentiation not only for HL-60 cells, but also for the phenotypically similar PLB-985 leukemic cells that share a common bipotential differentiation capacity; (2) differentiation blockade is cell-cell contact-dependent and is reversible; (3) K562 leukemic cells, despite binding to stromal cells in higher numbers than either HL-60 or PLB-985 cells, are not blocked in their chemically-induced differentiation along the megakaryocytic pathway; and (4) the differential susceptibility of HL-60/PLB-985 versus K562 cells to stromal cell inhibition correlates with the nature of contact at the intercellular interface, as assessed by SEM and cytoplasmic dye transfer.
Taken together, our findings support the notion that simple measurements of "cell numbers bound" in conventional cellcell binding analyses are not necessarily predictive of effective cellular interactions. In other words, the numbers of cells bound may not in fact be the critical parameter from the functional standpoint, but rather qualitative differences in the way particular cells bind to stromal cells may be of greater importance. More particularly, one can distinguish between "superficial In contrast, HL-60 and PLB-985 cells, which show intimate associations with stromal cells, as determined by ultrastructural analysis and cell-cell communication, are subject to stromal inhibition. Moreover, even among HL-60 cells themselves, only those tightly embedded within the stromal cell underlayer, but not those more superficially attached, become refractory to differentiation induction stimuli. This phenomenon may be analogous to the way in which hematopoietic stem cells within the BM microenvironment suppress differentiation signals found within the microenvironment to maintain their self-renewal capacity.6 Hence, it would seem that intimate contact between regulatory and regulated cells is a prerequisite for effective interactions, and differences in the type of contact may account for differential susceptibility of leukemic cells to stromal cell regulation. This study does not directly address the issue of molecular mechanisms underlying stromal inhibition. However, it does provide some insights in this regard. For example, it is clear from the present findings that simple physical proximity of stromal and leukemic cells, even with the cells touching each other, is not sufficient for the inhibitory effect. This tends to rule out the idea that the sole role of adhesion is to bring the regulated cell nearer to high levels of inhibitory factors produced by the regulating cell. This, of course, does not rule out a contributory role for stromal cell-derived molecules such as transforming growth factor P (TGFP)," which has been implicated in stromal cell-induced quiescence of adherent hematopoietic progenitors,'" and in fact, KM-102 stromal cells synthesize TGFPl and TGFP2 mRNA (M. Weber and M. Tykocinski, unpublished data).
Our studies indicate considerable intercellular communication between KM-IO2 cells and the HL-60, as well as the PLB-985, leukemic cell lines. The cytoplasmic dye transfer observed between stromal and leukemic cells is most likely mediated by gap-junction formation. Gap junctions are inter- This study introduces an improved method for monitoring stromal cell-mediated blockade of leukemic cell differentiation. In the previous Kh4-102-HG60 multure study," differentiation blockade was evaluated by determining the relative ability of the adherent leukemic cells to produce superoxide, as measure by the standard NBT reduction assay?' However, this experimental approach has several limitations. First, in our hands, we have observed considerable background NBT reduction by the stromal cells in the underlayer. Second, NBT is not an optimal marker for terminal leukemic differentiation because significant numbers of induced cells fail to express this phenotypic marker with certain chemical inducers. For example, only 60% of the la,25-dihydroxyvitamin D3-induced cells reduce NBT after 96 hours. Third, many of the HL-60 cells insinuate themselves in the stromal cell underlayer, precluding clearcut identification of all bound cells. Instead, our two-color immunofluorescence strategy uses an anti-CD18 antibody to identlfy HL-60 (or PLB-985) cells embedded within the adherent stromal cell layer, and anti-CD14 antibodies, a monocytic marker with greater sensitivity than NBT reduction, to identify differentiated HL-60 (or PLB-985) cells. This method can be readily adapted to other leukemic, or even nontransformed hematopoietic progenitor, cells to monitor effects upon differentiation.
The K"102 stromal cell line used in the present study provides a valuable cellular tool for studying hemoregulation. This line expresses a set of hematopoietic cytokines characteristic of primary BM stromal cells (M. Weber and M. Tykocinski, unpublished data). Moreover, as shown here, it retains the capacity to bind significant numbers of CD34+ hematopoietic progenitors. However, because stromal fibroblasts are known to be heterogeneous, it remains to be determined which types of stromal fibroblasts are capable of inhibiting leukemic cells.
Stromal cell effects upon leukemic cells have clinical implications. Major classes of leukemic therapeutics are based upon antiproliferative and/or differentiation-inducing modes of action. In fact, promising results have been reported after the use of differentiation-inducing agents, such as all-trans retinoic acid, to treat acute promyelocytic leukemia.31932 It is intriguing to speculate that stromal cells, by locking leukemia cells into a reversible, nonproliferatinglnondifferentiating state, render them refractory to antiproliferative and differentiation-inducing agents, and thereby contribute to clinical leukemia relapse. If confirmed, this would point the way towards the development of ancillary therapeutic agents aimed at interfering with this paradoxical stromal cell protective effect upon leukemia cells. Further insights into factors dictating variable leukemic cell susceptibility to stromal cell inhibitory effects will be a prerequisite for rational development of such antileukemia therapeutics.
